AUTOIMMUNE HEPATITIS AS A RARE UNDESIRABLE PHENOMENON OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C
- Authors: Tikhonova N.1, Lopatkina T.1, Odintsov A.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 24, No 8 (2013)
- Pages: 30-33
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115770
- ID: 115770
Cite item
Open Access
Access granted
Abstract
The immunomodulatory effect of interferon-а may cause autoimmune diseases and autoimmune phenomena in patients with their genetic predisposition and chronic hepatitis C, who receive antiviral therapy. The paper describes a case of interferon-induced severe autoimmune hepatitis requiring treatment discontinuation and long-term immunosuppressive therapy.
Full Text
About the authors
N. Tikhonova
I.M. Sechenov First Moscow State Medical University
T. Lopatkina
I.M. Sechenov First Moscow State Medical University
Email: lopatkina-tn@mail.ru
Candidate of Medical Sciences
A. Odintsov
I.M. Sechenov First Moscow State Medical University
References
- Лопаткина Т.Н. Нежелательные явления противовирусной терапии хронического гепатита С и методы их коррекции // Фарматека. 2006; 6: 106-9.
- Громова Н.И., Лопаткина Т.Н., Попова Е.Н. Внелегочный саркоидоз при комбинированной противовирусной терапии хронического гепатита С // Эпидемиол. и инфекцион. болезни. 2010; 6: 42-4.
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C // Hepatology. 1997; 26 (3 Suppl. 1): 112-21.
- Garcia-Buey L., Garcia-Monzon C., Rodriguez S. et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C // Gastroenterology. 1995; 108 (6):1770-7.
- Monti V., Aghemo A., Rumi M. et al. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies // Antivir. Ther. 2005; 10 (6): 715-20.
- Bai L., Feng Z., Lu H. et al. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China // Chin. Med. J. (Engl.). 2009; 122 (1): 5-9.
- Lunel F., Abuaf N., Frangeul L. et al. Anti-liver/kidney microsome antibody type I and hepatitis C virus infection // Hepatology. 1992; 16: 630-6.
- Лопаткина Т.Н. Аутоиммунный гепатит и перекрестные синдромы // Фарматека. 2010; 15: 62-8.
- Kogure T., Ueno Y., Fukushima K. et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment // World J. Gastroenterol. 2007; 13 (32): 4394-7.
- Yu M., Lin S., Chuang W. et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan // Antivir. Ther. -2006; 11 (8): 985-94.
- Petersen-Benz C., Kasper H., Dries V. et al. Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis C-autoimmune hepatitis overlap syndrome // Clin. Gastroenterol. Hepatol. 2004; 2 (5): 440-3.
- Azhar A., Niazi M., Tufail K. et al. A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome // Gastroenterol. Hepatol. (N.-Y). 2010; 6 (4): 233-6.
- Rahmani R., Schiano T. Hepatitis C Autoimmune Hepatitis Overlap Syndrome: Review // Gastroenterol. Hepatol. 2010; 6 (4): 236-8.
- Yasui S., Fujiwara K., Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity // Digest. Liver Dis. 2011; 43: 665-7.
- Kato H., Ikeuchi H., Nakamura M. Acute Exacerbation of Liver Disease Induced by Pegylated Interferon Alpha2a Treatment for Chronic Hepatitis C // Int. J. Clin. Med. 2010; 1: 1-5.
Supplementary files
